Impact of Biophoton Therapy on Chronic Severe Arthritis Pain

Launched by FIRST INSTITUTE OF ALL MEDICINES · Apr 1, 2025

Keywords

ClinConnect Summary

This clinical trial is studying whether a treatment called biophoton therapy can help reduce chronic severe pain in people with arthritis. The therapy uses special devices called Tesla BioHealing® Biophoton Generators, which participants will use while they sleep. About 102 people, aged 18 to 80, with at least three months of ongoing arthritis pain rated at 5 out of 10 or higher will be eligible to join. Participants will be randomly assigned to either the treatment group, who will use the active devices, or a control group, who will use similar devices that do not have the active therapy. Both groups will participate in the study for 12 weeks, and neither the participants nor the study staff will know who is receiving the actual therapy to ensure fair results.

Throughout the study, participants will complete various questionnaires to track changes in their pain levels and overall quality of life. After the initial 12 weeks, those in the control group may have the option to switch to the active treatment for an additional 4 to 12 weeks. It's important to note that participants must be fluent in English and able to commit to the study requirements. Certain health conditions and treatments may disqualify individuals from participating, such as untreated psychiatric issues or specific medical devices like pacemakers. This study aims to find out if biophoton therapy can effectively help people manage their arthritis pain.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Willing and able to give informed consent for participation in the trial.
• • Is able and willing to comply with all trial requirements.
• • Male or female aged 18-80 years old with chronic severe arthritis pain.
• • ≥3 months duration of chronic severe arthritis pain.
• • a current VAS pain rating ≥5/10.
• • Able to complete the treatment for the study period.
• • Must be fluent in English.
• Exclusion Criteria:
• • Untreated psychiatric disturbances that would affect trial participation as judged by the Caregiver or by the clinical study medical professional
• • Who relies on ventilators
• • Who had deep brain stimulators, or pacemakers, or implantable electronic devices
• • Co-morbid conditions that would interfere with study activities or response to treatment, which may include severe chronic pulmonary disease, history of uncontrolled seizures, acute or chronic infectious illness, severe diabetes, kidney failure, or any end-of-life prognosis.
• • Is participating in another investigational drug or device trial
• • Has an active infectious disease, such as COVID-19
• • Pregnant women.